Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor. - Wikidata - wikimedia - TriplyDB

Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.

Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.

http://www.wikidata.org/entity/Q33902628

about

Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes Critical appraisal of ticagrelor in the management of acute coronary syndrome Platelet volume indices are associated with systolic and diastolic cardiac dysfunction, and left ventricular hypertrophy.Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor Effect of Oral Anti-platelet Regimens on Platelet Aggregation using Chronolog Light Transmittance Aggregometry in Coronary Heart Disease Patients: An Observational Study.Ticagrelor: An emerging oral antiplatelet agent.Dual antiplatelet therapy and newer agents: More efficacy but lets keep the brain safe!!

P2860

Q24631111-11B7511E-9BB1-4458-AEB2-239A8D7B16E4 Q35660767-22C5B0D3-8728-4F83-8FC3-3FA1B809636D Q35664650-42EB5381-0D76-4A53-B355-FE8A1FD2DEA1 Q36807413-D757CB65-6AB6-409D-93D4-384FF7759605 Q37429557-0E900355-8750-494E-B66A-0A6A3BFE0AEE Q40359329-42ADFCA8-F958-437A-8424-EB165BECD805 Q42945099-A3501635-7E3A-40FB-A4B5-23A9EDFFBEB4

P2860

Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.

http://www.wikidata.org/entity/Q33902628

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Novel antiplatelet agents in t ...... ications--focus on ticagrelor.

@ast

Novel antiplatelet agents in t ...... ications--focus on ticagrelor.

@en

type

label

Novel antiplatelet agents in t ...... ications--focus on ticagrelor.

@ast

Novel antiplatelet agents in t ...... ications--focus on ticagrelor.

@en

prefLabel

Novel antiplatelet agents in t ...... ications--focus on ticagrelor.

@ast

Novel antiplatelet agents in t ...... ications--focus on ticagrelor.

@en

P1433

Q33902628-A8474301-B838-4E0A-961C-F09267844276

P1476

Q33902628-C8C4D37F-5F7D-4126-838D-C82D6A55DFA9

P2093

Q33902628-22B7691A-F104-40B1-B8A3-392210AA4663

Q33902628-75D3EA4A-FDC4-4B2D-BC67-D84A70D17F8D

Q33902628-D081B271-B23E-4B8C-853A-CA72A94AA0A6

P2860

Q33902628-08F95D5A-1CED-4CBD-9640-4C345A6B1698

Q33902628-0A452E5F-25B8-4357-A5EA-079C4D86F928

Q33902628-0B4830BC-70ED-4EF8-9284-1BCFE338BCAD

Q33902628-137FB79E-A103-4D2D-8B54-6D06B5727343

Q33902628-1721E70B-AB5A-42B2-B263-30902A73DE0B

Q33902628-1A57D839-AA3F-412D-A45A-E5B9637D430E

Q33902628-1B4C9192-BE06-40D4-AD0A-9526356C2348

Q33902628-1DAA3985-7CD9-402F-8C2A-B744681122DC

Q33902628-1DDADB6C-7BC7-486F-BCDA-4FA2FF4BC9F5

Q33902628-1EBB9804-EF7E-4AEE-9854-884BB3A8C2E9

P304

Q33902628-FD1BD87D-3E4B-485C-B9AA-8B84B7DBA6A7

P31

Q33902628-37FF72C0-6D1D-4357-AF46-C9F26C2AA012

Q33902628-DE369D83-CDA9-433C-B293-254946D02DF7

P407

Q33902628-A7577C0A-31CD-437A-8BF8-E101F3FE1402

P478

Q33902628-70FC2472-731F-41BF-9D3A-4ADA9C12F91D

P577

Q33902628-F31E4F00-8765-473B-AD4A-E3F9D70617A0

P698

Q33902628-E38594B2-E0FE-49D1-B315-7F3351BEA079

P921

Q33902628-02BF882A-B94B-4CDD-866D-A39A48C7060C

Q33902628-1BEA8A42-550F-48BA-BF74-B6138EED9F2F

Q33902628-34A4096A-861A-4477-AF97-3D0F4BF1E1FB

Q33902628-4BB01F63-5BF5-46C0-B468-462F6CEFA84F

Q33902628-5844B4E6-8331-48B7-8F44-5D8B42B259ED

Q33902628-F669E9D3-3236-4C36-993D-534F36C1A0FA

P932

Q33902628-1A364AB0-A313-4311-9710-C4EBA0D5CC33

P1433

Vascular Health and Risk Management

P1476

Novel antiplatelet agents in t ...... ications--focus on ticagrelor.

@en

P2093

Dariusz Kosior

http://www.w3.org/2001/XMLSchema#string

Marek Postula

http://www.w3.org/2001/XMLSchema#string

Margaret M Marczewski

http://www.w3.org/2001/XMLSchema#string

P2860

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

The P2Y1 receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models

P304

419-429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20539844

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

heterocyclic compound

pharmaceutical preparation

hemic and immune systems

P932

2882894

http://www.w3.org/2001/XMLSchema#string